Copeland Capital Management LLC Sells 24,419 Shares of iRadimed Corporation $IRMD

Copeland Capital Management LLC lessened its holdings in iRadimed Corporation (NASDAQ:IRMD) by 5.3% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 433,500 shares of the medical equipment provider’s stock after selling 24,419 shares during the quarter. Copeland Capital Management LLC’s holdings in iRadimed were worth $30,848,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Jump Financial LLC raised its stake in shares of iRadimed by 4.9% during the first quarter. Jump Financial LLC now owns 4,300 shares of the medical equipment provider’s stock valued at $226,000 after acquiring an additional 200 shares during the last quarter. CWM LLC raised its position in iRadimed by 62.2% during the 3rd quarter. CWM LLC now owns 550 shares of the medical equipment provider’s stock worth $39,000 after purchasing an additional 211 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in iRadimed by 5.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,811 shares of the medical equipment provider’s stock worth $252,000 after purchasing an additional 234 shares during the last quarter. State of Wyoming lifted its holdings in iRadimed by 11.3% during the 1st quarter. State of Wyoming now owns 3,013 shares of the medical equipment provider’s stock worth $158,000 after buying an additional 307 shares during the period. Finally, Hsbc Holdings PLC grew its position in shares of iRadimed by 3.4% in the 1st quarter. Hsbc Holdings PLC now owns 11,912 shares of the medical equipment provider’s stock valued at $614,000 after buying an additional 392 shares during the last quarter. 92.34% of the stock is currently owned by institutional investors and hedge funds.

iRadimed Stock Up 0.3%

iRadimed stock opened at $97.74 on Tuesday. The company has a market capitalization of $1.24 billion, a PE ratio of 59.24 and a beta of 1.06. iRadimed Corporation has a 12-month low of $47.48 and a 12-month high of $98.53. The firm’s fifty day moving average is $89.18 and its 200 day moving average is $74.61.

iRadimed (NASDAQ:IRMD) last posted its quarterly earnings results on Monday, November 3rd. The medical equipment provider reported $0.47 EPS for the quarter, topping analysts’ consensus estimates of $0.43 by $0.04. iRadimed had a net margin of 26.31% and a return on equity of 22.93%. The business had revenue of $21.20 million during the quarter, compared to analysts’ expectations of $20.50 million. iRadimed has set its Q4 2025 guidance at 0.470-0.510 EPS and its FY 2025 guidance at 1.840-1.880 EPS. Sell-side analysts expect that iRadimed Corporation will post 1.66 EPS for the current fiscal year.

iRadimed Announces Dividend

The company also recently declared a special dividend, which will be paid on Tuesday, December 30th. Investors of record on Wednesday, December 17th will be paid a dividend of $0.50 per share. The ex-dividend date of this dividend is Wednesday, December 17th. iRadimed’s dividend payout ratio is 41.21%.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on IRMD. Lake Street Capital restated a “buy” rating and set a $100.00 price objective on shares of iRadimed in a research report on Monday, November 3rd. Weiss Ratings restated a “buy (b-)” rating on shares of iRadimed in a report on Monday, December 22nd. Roth Capital set a $90.00 price target on shares of iRadimed in a research report on Friday, October 31st. Zacks Research upgraded shares of iRadimed to a “hold” rating in a research report on Tuesday, November 4th. Finally, Wall Street Zen downgraded shares of iRadimed from a “strong-buy” rating to a “buy” rating in a research note on Sunday, October 26th. Four research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $87.33.

Insider Activity at iRadimed

In other iRadimed news, CEO Roger E. Susi sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, December 22nd. The stock was sold at an average price of $96.73, for a total value of $483,650.00. Following the completion of the sale, the chief executive officer owned 2,287,500 shares of the company’s stock, valued at approximately $221,269,875. This trade represents a 0.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO John Glenn sold 15,000 shares of the company’s stock in a transaction that occurred on Thursday, December 11th. The stock was sold at an average price of $97.29, for a total value of $1,459,350.00. Following the transaction, the chief financial officer directly owned 7,362 shares in the company, valued at $716,248.98. The trade was a 67.08% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 65,000 shares of company stock worth $5,548,150. Corporate insiders own 36.80% of the company’s stock.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.